Compare Stocks: EVFM, GRI, GLMD, and REVB

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
EVFM Evofem Biosciences	$0.01 +2.7%	$0.01	$0.00 ▼ $0.02	$1.02M	-1.31	219,803 shs	52,384 shs
GLMD Galmed Pharmaceuticals	$3.88 -1.0%	$4.39	$3.29 ▼ $13.20	$4.08M	0.67	43,670 shs	4,100 shs
GRI GRI Bio	$2.88 +25.8%	$1.73	$1.36 ▼ $80.36	$5.01M	-1.24	508,950 shs	7.41 million shs
REVB Revelation Biosciences	$1.01 -0.2%	$1.06	$0.88 ▼ $11.60	$4.02M	-0.14	43,186 shs	7,734 shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
EVFM Evofem Biosciences	+2.67%	+2.67%	-8.33%	-6.10%	-18.95%
GLMD Galmed Pharmaceuticals	-1.02%	-6.73%	-16.38%	-30.32%	-62.40%
GRI GRI Bio	+25.76%	+50.00%	+88.24%	+44.00%	-92.95%
REVB Revelation Biosciences	-0.20%	-4.00%	-12.35%	+1.82%	-90.77%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
EVFM Evofem Biosciences	$0.01 +2.7%	$0.01	$0.00 ▼ $0.02	$1.02M	-1.31	219,803 shs	52,384 shs
GLMD Galmed Pharmaceuticals	$3.88 -1.0%	$4.39	$3.29 ▼ $13.20	$4.08M	0.67	43,670 shs	4,100 shs
GRI GRI Bio	$2.88 +25.8%	$1.73	$1.36 ▼ $80.36	$5.01M	-1.24	508,950 shs	7.41 million shs
REVB Revelation Biosciences	$1.01 -0.2%	$1.06	$0.88 ▼ $11.60	$4.02M	-0.14	43,186 shs	7,734 shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
EVFM Evofem Biosciences	+2.67%	+2.67%	-8.33%	-6.10%	-18.95%
GLMD Galmed Pharmaceuticals	-1.02%	-6.73%	-16.38%	-30.32%	-62.40%
GRI GRI Bio	+25.76%	+50.00%	+88.24%	+44.00%	-92.95%
REVB Revelation Biosciences	-0.20%	-4.00%	-12.35%	+1.82%	-90.77%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
EVFM Evofem Biosciences	0.00	N/A	N/A	N/A
GLMD Galmed Pharmaceuticals	1.00	Sell	N/A	N/A
GRI GRI Bio	2.00	Hold	$32.00	1,011.11% Upside
REVB Revelation Biosciences	1.00	Sell	N/A	N/A

Current Analyst Ratings Breakdown

Latest EVFM, GRI, GLMD, and REVB Analyst Ratings

Date	Company	Brokerage	Action	Rating
8/25/2026	REVB Revelation Biosciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (E+) ➝ Sell (E)
8/11/2026	REVB Revelation Biosciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E) ➝ Sell (E+)
7/28/2026	REVB Revelation Biosciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (E+) ➝ Sell (E)
7/17/2026	GLMD Galmed Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/17/2026	GRI GRI Bio	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/9/2026	REVB Revelation Biosciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E) ➝ Sell (E+)
6/18/2026	REVB Revelation Biosciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (E+) ➝ Sell (E)

(Data available from 9/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
EVFM Evofem Biosciences	$11.39M	0.09	N/A	N/A	($2.64) per share	0.00
GLMD Galmed Pharmaceuticals	N/A	N/A	N/A	N/A	$23.04 per share	N/A
GRI GRI Bio	N/A	N/A	N/A	N/A	$4.70 per share	N/A
REVB Revelation Biosciences	N/A	N/A	N/A	N/A	$2.53 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
EVFM Evofem Biosciences	$52.98M	-$0.13	N/A	N/A	N/A	-46.42%	-91.97%	-61.93%	N/A
GLMD Galmed Pharmaceuticals	-$10.31M	-$15.18	N/A	N/A	N/A	N/A	-73.68%	-60.88%	N/A
GRI GRI Bio	-$11.96M	-$38.37	N/A	N/A	N/A	N/A	-134.03%	-106.83%	11/13/2026 (Estimated)
REVB Revelation Biosciences	-$8.91M	-$12.31	N/A	N/A	N/A	N/A	-100.19%	-82.72%	11/5/2026 (Estimated)

Latest EVFM, GRI, GLMD, and REVB Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
9/2/2026	Q2 2026	GLMD Galmed Pharmaceuticals	-$3.12	-$2.86	+$0.26	-$2.86	N/A	N/A
8/14/2026	Q2 2026	GRI GRI Bio	-$1.19	-$0.91	+$0.28	-$0.91	N/A	N/A
8/6/2026	Q2 2026	REVB Revelation Biosciences	-$0.8750	-$0.87	+$0.0050	-$0.87	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
EVFM Evofem Biosciences	N/A	N/A	N/A	N/A	N/A
GLMD Galmed Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
GRI GRI Bio	N/A	N/A	N/A	N/A	N/A
REVB Revelation Biosciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
EVFM Evofem Biosciences	N/A	0.11	0.09
GLMD Galmed Pharmaceuticals	N/A	4.16	7.71
GRI GRI Bio	N/A	10.30	10.30
REVB Revelation Biosciences	N/A	6.22	6.22

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
EVFM Evofem Biosciences	0.22%
GLMD Galmed Pharmaceuticals	76.14%
GRI GRI Bio	33.95%
REVB Revelation Biosciences	12.80%

Insider Ownership

Company	Insider Ownership
EVFM Evofem Biosciences	0.01%
GLMD Galmed Pharmaceuticals	19.80%
GRI GRI Bio	8.73%
REVB Revelation Biosciences	4.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
EVFM Evofem Biosciences	120	132.53 million	113.12 million	Not Optionable
GLMD Galmed Pharmaceuticals	20	1.04 million	836,000	Not Optionable
GRI GRI Bio	1	2.19 million	2.00 million	Not Optionable
REVB Revelation Biosciences	10	3.98 million	3.79 million	Not Optionable

EVFM, GRI, GLMD, and REVB Headlines

Recent News About These Companies

Revelation Biosciences Selects Avance Clinical as CRO for Phase 2/3 TITAN Study

August 19, 2026 | finance.yahoo.com

REVB approaching a critical inflection point

August 7, 2026 | msn.com

Revelation Biosciences, Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2026

August 6, 2026 | accessnewswire.comA

Independent Market Assessment Results Show $94 Billion Total Addressable Market for Gemini in Stage 2 and Stage 3 Acute Kidney Injury

August 3, 2026 | accessnewswire.comA

Revelation Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

July 21, 2026 | accessnewswire.comA

Revelation Biosciences, Inc.: Revelation Biosciences Announces Adoption of Stockholder Rights Plan

July 10, 2026 | finanznachrichten.de

Revelation Biosciences Announces Adoption of Stockholder Rights Plan

July 10, 2026 | accessnewswire.comA

Revelation Biosciences Expands Acute Kidney Injury Advisory Board

June 1, 2026 | accessnewswire.comA

Revelation Biosciences, Inc. Releases Corporate Update Letter to Stockholders

May 11, 2026 | accessnewswire.comA

REVB Poised for Big Year

May 8, 2026 | finance.yahoo.com

Revelation Biosciences, Inc. Announces Financial Results For the Three Months Ended March 31, 2026

May 7, 2026 | accessnewswire.comA

Revelation Biosciences Announces Formation of Acute Kidney Injury Advisory Board

April 6, 2026 | accessnewswire.comA

Revelation Biosciences Inc. Presents Additional Positive Data from Prime Clinical Study

March 30, 2026 | oklahoman.comO

Revelation Biosciences (REVB) price target decreased by 37.65% to 54.06

March 28, 2026 | msn.com

REMINDER: Revelation Biosciences to Host Fireside Chat at 38th Annual Roth Conference

March 24, 2026 | accessnewswire.comA

Revelation Biosciences to Host Fireside Chat at 38th Annual Roth Conference

March 19, 2026 | accessnewswire.comA

Revelation Biosciences, Inc. Announces Financial Results For the Three and Twelve Months Ended December 31, 2025

February 26, 2026 | accessnewswire.comA

Revelation Biosciences (REVB) price target increased by 300.00% to 86.70

February 4, 2026 | msn.com

REVB Comes to Agreement with FDA

January 29, 2026 | finance.yahoo.com

REVB stock drops 10% after company announces third reverse split in a year

January 26, 2026 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

EVFM, GRI, GLMD, and REVB Company Descriptions

Evofem Biosciences NASDAQ:EVFM

$0.0077 +0.00 (+2.67%)

As of 09/4/2026 03:48 PM Eastern

Evofem Biosciences, Inc., a biopharmaceutical company, develops and commercializes various products to address unmet needs in women's sexual and reproductive health. Its commercial product is Phexxi, a vaginal gel for the prevention of pregnancy. The company is also involved in the development of EVO100 for the prevention of chlamydia and gonorrhea in Women, and EVO200 for the prevention of recurrent bacterial vaginosis. Evofem Biosciences, Inc. is headquartered in San Diego, California.

Galmed Pharmaceuticals NASDAQ:GLMD

$3.93 +0.01 (+0.33%)

As of 09/4/2026 03:57 PM Eastern

Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. It has a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Tel Aviv, Israel.

GRI Bio NASDAQ:GRI

$2.88 +0.59 (+25.76%)

As of 09/4/2026 04:00 PM Eastern

GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on treating inflammatory, fibrotic, and autoimmune diseases in the United States. Its product pipeline comprises GRI-0621, which is in phase II clinical development for the treatment of idiopathic pulmonary fibrosis; GRI-0803 which is in phase I trial for the treatment of systematic lupus erythematosus; GRI-0124, which is in pre-clinical development for the treatment of primary sclerosing cholangitis; and GRI-0729 in pre-clinical development. The company also develops ADAIR and ADMIR for treatment of attention -deficit/hyperactivity disorder. GRI Bio, Inc. was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.

Revelation Biosciences NASDAQ:REVB

$1.01 0.00 (-0.20%)

As of 09/4/2026 03:50 PM Eastern

Revelation Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-SSI, a potential therapy for the prevention and treatment of surgical sit infection; GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease. The company was founded in 2020 and is based in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest EVFM, GRI, GLMD, and REVB Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest EVFM, GRI, GLMD, and REVB Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

EVFM, GRI, GLMD, and REVB Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

EVFM, GRI, GLMD, and REVB Company Descriptions

Evofem Biosciences NASDAQ:EVFM

Galmed Pharmaceuticals NASDAQ:GLMD

GRI Bio NASDAQ:GRI

Revelation Biosciences NASDAQ:REVB

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest EVFM, GRI, GLMD, and REVB Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest EVFM, GRI, GLMD, and REVB Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

EVFM, GRI, GLMD, and REVB Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

EVFM, GRI, GLMD, and REVB Company Descriptions

Evofem Biosciences NASDAQ:EVFM

Galmed Pharmaceuticals NASDAQ:GLMD

GRI Bio NASDAQ:GRI

Revelation Biosciences NASDAQ:REVB

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools